Pharmacovigilance Shifts From Task Automation to AI Decision Support

Pharmaceutical safety teams are confronting a fundamental operational challenge: exponentially growing data volumes paired with increasingly complex global reporting requirements. While the industry spent years automating repetitive tasks like data entry and intake processing, those gains have reached their ceiling. The bottleneck has shifted to decision-making itself—specifically, the time safety professionals spend gathering fragmented information before they can evaluate risk.

According to Deloitte's 2026 Life Sciences Outlook, 48% of life sciences executives identify digital technologies and data analytics as substantial organizational impacts, while 30% flag agentic AI as a priority area. Organizations adopting AI-supported safety workflows have increased reporting throughput by approximately 40% without expanding review teams, according to reporting first published by Drug Discovery Trends.

Why it matters

Pharmaceutical companies face regulatory obligations that cannot be met by simply hiring more reviewers. AI systems that consolidate evidence from disparate sources—literature databases, regulatory filings, real-world evidence, internal systems—allow safety experts to focus on clinical judgment rather than data retrieval. Some organizations now move more than 96% of cases through automated submission pathways, fundamentally changing expectations around modern safety operations.

Traditional Automation Addressed Intake, Not Analysis

The first wave of pharmacovigilance modernization targeted transactional work: standardizing forms, automating data entry, streamlining case intake. These investments improved consistency and freed safety professionals from manual transformation tasks. But downstream processes remained manual and fragmented.

Safety teams still compare emerging trends against historical patterns, examine literature databases, review regulatory reporting data, and evaluate supporting evidence before escalating concerns. When contextual information exists across disconnected repositories, professionals spend more time assembling evidence than interpreting it. AI-assisted workflows have compressed average case timelines from company receipt to final submission to under two hours, according to the report.

The barrier to broader adoption is not regulatory hesitation but internal readiness. Organizations must rethink governance models, escalation protocols, and review workflows alongside the technology itself.

AI Agents Reshape Signal Detection Through Evidence Aggregation

Signal detection traditionally begins when a reviewer identifies an emerging pattern, then manually gathers supporting context from literature systems, sales data, regulatory sources, and external reporting databases before conducting clinical evaluation. Human expertise bookends the process, but information retrieval consumes significant time in between.

Agentic AI can orchestrate those steps simultaneously, aggregating relevant evidence into unified packages before human evaluation begins. This allows safety professionals to focus expertise directly on assessing clinical significance and determining appropriate action. IQVIA's Vigilance Detect achieved 94% precision and 99% accuracy in audio review for one client, alongside an 81% reduction in manual review workload.

Decision Velocity Becomes the Competitive Differentiator

As pharmaceutical portfolios expand, successful AI adoption depends on internal readiness, data quality, and contextual consistency. AI systems cannot reliably transform unstructured documents into safety workflows without scientific context, standardized inputs, and high-quality data.

The most effective organizations combine AI-driven orchestration with strong human oversight. The industry conversation is shifting from whether PV teams need AI to how organizations can deploy it responsibly while preserving scientific rigor and regulatory trust.

Updesh Dosanjh, Practice Leader for Pharmacovigilance Technology Solutions at IQVIA, notes that pharmacovigilance will always require human expertise in the loop, but AI may finally allow safety professionals to spend less time searching for information and more time applying clinical judgment. These details were first reported by Drug Discovery Trends.